A Phase1 Study, to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Doses of Orally Administered HM71224 in Healthy, Adult Male Volunteers

Trial Profile

A Phase1 Study, to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Doses of Orally Administered HM71224 in Healthy, Adult Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2015

At a glance

  • Drugs Poseltinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 17 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Jun 2014 According to a Hanmi Pharmaceuticals media release, interim results of this trial were presented at the Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top